Literature DB >> 10927146

The effect of nicotinamide on spontaneous and induced activity in smooth and skeletal muscle.

M W Ruddock1, D M Burns, L E Murphy, M G O'Rourke, D G Hirst.   

Abstract

BACKGROUND AND
PURPOSE: Nicotinamide (NA) is currently undergoing clinical trials as a tumour radiosensitizer. The dose that can be administered is currently 80 mg/kg per day, but this may be restricted to 60 mg/kg per day by the high incidence of nausea and vomiting. To investigate some of NA's underlying mechanisms of action, we have used an ex vivo system to study the direct effect of this drug, over a wide range of concentrations, on isolated spontaneously active rat ileum. Effects on the gut were compared with the action of NA on skeletal and vascular smooth muscle.
MATERIALS AND METHODS: Isolated rat ileum rings were perfused with oxygenated Krebs' solution in an organ bath. NA (1 microM to 10 mM) was introduced to the perfusate and the change in amplitude of spontaneous peristaltic activity recorded. Dissected frog sartorius muscle was bathed in modified oxygenated Ringer's solution in an organ bath. The muscle was electrically stimulated to generate isometric contractions. Tension was then measured before and after the addition of a range of NA concentrations (8.2-24.6 mM) to the organ bath.
RESULTS: NA inhibited peristalsis in the ileum in a dose-dependent manner. At a drug concentration of 1 mM the amplitude of contractions was reduced to <50% of the initial control value. NA had no effect on the electrically induced contractions in the isolated frog sartorius muscle.
CONCLUSIONS: Gut smooth muscle is highly sensitive to the relaxant effect of NA producing 50% relaxation at a concentration approximately 10 fold lower than that required in rat arterial smooth muscle, while having no effect on non-mammalian skeletal smooth muscle. This may provide explanations for the occurrence of emesis in patients undergoing combined nicotinamide therapies and highlight possible alternatives available to counter this unwanted side-effect.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10927146     DOI: 10.1016/s0167-8140(00)00194-8

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  2 in total

1.  N-Methyl-2-pyridone-5-carboxamide is 1-methylnicotinamide metabolite of low cyclooxygenase-dependent vasodilating activity.

Authors:  Tomasz Przygodzki; Bartlomiej Grobelski; Piotr Kazmierczak; Cezary Watala
Journal:  J Physiol Biochem       Date:  2012-01-13       Impact factor: 4.158

2.  Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?

Authors:  Majid Ali; Brian A Telfer; Cian McCrudden; Martin O'Rourke; Huw D Thomas; Marzieh Kamjoo; Suzanne Kyle; Tracy Robson; Chris Shaw; David G Hirst; Nicola J Curtin; Kaye J Williams
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.